This inventor holds 1 USPTO granted patent. Top assignee: Bs-154 S.p. Zo.o.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Jan Mazerski: Innovator in Cytostatics
Introduction
Jan Mazerski is a notable inventor based in Gdansk, Poland. He has made significant contributions to the field of cytostatics, particularly through his innovative research and development of new chemical compounds. His work focuses on creating effective treatments for tumor cells, especially those exhibiting multidrug resistance.
Latest Patents
Jan Mazerski holds a patent for "Asymmetrically substituted anthrapyridazone derivatives as cytostatics." This invention relates to new, asymmetrically substituted derivatives of 2,7-dihydro-3H-dibenzo[de,h]cinnoline-3,7-dione. These derivatives are designed to exhibit activity against tumor cells, providing a potential solution for patients facing multidrug resistance (MDR). The patent highlights the general formula (I) for these derivatives, showcasing their unique chemical structure and potential therapeutic applications.
Career Highlights
Throughout his career, Jan Mazerski has demonstrated a commitment to advancing medical science through innovative research. His work has not only contributed to the understanding of cytostatics but has also paved the way for new treatment options for cancer patients. His dedication to research and development has established him as a respected figure in the scientific community.
Collaborations
Jan has collaborated with esteemed colleagues, including Edward Borowski and Barbara J Stefanska. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their research.
Conclusion
Jan Mazerski's contributions to the field of cytostatics exemplify the importance of innovation in medical research. His patented work on asymmetrically substituted anthrapyridazone derivatives represents a significant advancement in the fight against cancer. Through his dedication and collaboration with fellow researchers, he continues to make strides in developing effective treatments for patients in need.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile